Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

This publication has 31 references indexed in Scilit:

• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
  Nature Medicine, 2013
• Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2011
• Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules
  Scientific Reports, 2011
• A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
  British Journal of Cancer, 2010
• Following TRAIL’s path in the immune system
  Immunology, 2009
• Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
  Journal of Clinical Oncology, 2009
• Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
  Blood, 2008
• TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
  Drug Resistance Updates, 2008
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily
  Nature Reviews Cancer, 2002
• Safety and antitumor activity of recombinant soluble Apo2 ligand
  Journal of Clinical Investigation, 1999